Phase 2 N=30 Molecular Profiling in Lung Cancer Patients
Non-Small Cell Lung Cancer · Carcinoma
Primary: High/Low Expression of Selected Molecular Markers in Tumor Tissues and Hypermethylated Genes in Peripheral Blood
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=295 Long-term Open-label Trial in Idiopathic Restless Legs Syndrome (RLS)
Restless Legs Syndrome
Primary: Number of Subjects With at Least One Adverse Event, as Reported Spontaneously by the Subject or Observed by the Investigator, During the 5-year Open-label Extension…
Phase 2 N=52 Study of Two Formulations of Buprenorphine HCl in Opioid-dependent Subjects on Buprenorphine Maintenance Therapy (Study P04451) (COMPLETED)
Opioid Dependency
Primary: The Overall Preference Between Two Buprenorphine Sublingual Formulations, After a Switch From the Marketed Tablet (Subutex®) to the New Fast Dissolving Tablet (FDT), in…
Phase 2 N=10 Rilonacept to Improve Artery Function in Patients With Atherosclerosis
Coronary Artery Disease · Atherosclerosis · Inflammation
Primary: C-Reactive Protein (CRP) — 3.7; 4.6 mg/L
Phase 2 N=179 Safety and Efficacy of an Investigational Drug in Human Immunodeficiency Virus (HIV)-Infected Patients Failing Current Antiretroviral Therapies (0518-005)(COMPLETED)
HIV Infections · Acquired Immunodeficiency Syndrome
Primary: Change From Baseline in Plasma HIV RNA (log10 Copies/mL) at Week 24 — -1.80; -1.87; -1.84; -0.35 HIV RNA (log10 copies/mL)
Phase 2 N=23 A Study to Evaluate the Pharmacokinetic Profile (How the Body Absorbs, Distributes, Metabolizes and Eliminates a Drug) of TMC125 Plus Tenofovir/Emtricitabine Once Daily With or Without Darunavir/r Once Daily in Antiretroviral (ARV) Naive HIV-1 Patients (Patients Have Never Received ARV Treatment).
HIV-1 Infection
Primary: Number of Participants Contributing to the Pharmacokinetic (PK) Evaluations: Cmin, Cmax, AUC24 & Css,av — 23; 21 participants
Phase 2 N=180 Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Graft vs Host Disease · Immune System Disorders
Primary: Number of Complete Response (CR) at Day 28 of Therapy — 12; 27; 25; 16 participants
Phase 2 N=2,409 Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005)
HPV 16 Infection
Primary: Incidence of Persistent HPV 16 Infection — 0.3; 4.9 Incidence per 100 person-years
Phase 2 N=53 Effect of LY686017 on Alcohol Craving
Alcohol Dependence · Alcoholism
Primary: Craving for Alcohol (Spontaneous) — 19.7; 19.1 Units on a scale
Phase 2 N=52 BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)
Cancer · Carcinoma, Non-Small Cell Lung
Primary: Anti-cancer Activity (eg, Percentage of Patients With Confirmed Complete Responses (CR) and Partial Responses (PR) Per RECIST (Response Evaluation Criteria in Solid…
Phase 2 N=45 Prospective Randomized Double Blind Clinical Trial of Polyhexamethylene Biguanide Impregnated Foam Dressing
Wounds
Primary: Prevalence of Signs of Critical Colonization, Deep Infection, and Wound Healing Between the Two Groups
Phase 2 N=47 A Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer (BRIDGE)
Non-small Cell Lung Cancer
Primary: Incidence of Grade ≥3 Pulmonary Hemorrhage Adverse Events — 3.2 Percentage of patients
Phase 2 N=153 Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis
Chronic Kidney Disease on Hemodialysis · Secondary Hyperparathyroidism
Primary: Percentage of Subjects With ≥ 50% Decrease From Baseline in Intact Parathyroid Hormone (iPTH) Serum Level — 53.3; 41.9; 38.7; 56.7 Percentage of participants
Phase 2 N=35 Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma
Carcinoma, Renal Cell
Primary: Number of Subjects With Overall Confirmed Objective Disease Response According to the Response Evaluation Criteria in Solid Tumors (RECIST) — 13 participants
Phase 2 N=34 Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.
Kidney Failure, Chronic · Diabetic Nephropathies · Glomerulonephritis, IGA
Primary: The Number of Subjects With a 10% Decrease in PRA Level at Month 8. — 9 Participant